| Dr Cameron Michael Hofer, DPT | |
|
801 S Raymond Ave, Pasadena, CA 91105-3223 | |
| (626) 356-0599 | |
| Not Available |
| Full Name | Dr Cameron Michael Hofer |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 801 S Raymond Ave, Pasadena, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023733946 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 302996 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cameron Michael Hofer, DPT 308 N Soldano Ave, Azusa, CA 91702-3640 Ph: (503) 547-9407 | Dr Cameron Michael Hofer, DPT 801 S Raymond Ave, Pasadena, CA 91105-3223 Ph: (626) 356-0599 |
News Archive
A study in the April 15 issue of the Journal of Clinical Sleep Medicine shows increased automobile crash rates among teen drivers who start school earlier in the morning.
President Barack Obama's executive order said a working group chaired by Office of National AIDS Policy Director Grant Colfax and Health and Human Services Secretary Kathleen Sebelius would have 180 days to deliver its recommendations.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
With the rapid and continuous advances in biotechnology, scientists are better able to see inside the nucleus of a cell to unlock the secrets of its genetic material. However, what happens outside of the nucleus has, in many ways, remained a mystery. Now, researchers with the National Institutes of Health are closer to understanding how activity outside of the nucleus determines a cell's behavior.
Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.
› Verified 6 days ago
Stephany Tritt, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1158 E Colorado Blvd, Pasadena, CA 91106 Phone: 323-314-3415 Fax: 323-982-9018 | |
Tiffany Lorraine Waniczek-nowicki, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 200 E Del Mar Blvd Ste 302, Pasadena, CA 91105 Phone: 626-683-8536 | |
Trenton Nakama, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1224 E Green St Fl 2, Pasadena, CA 91106 Phone: 626-356-4948 | |
Vincent Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2615 E Washington Blvd, Pasadena, CA 91107 Phone: 626-798-5074 Fax: 626-798-3210 | |
Andrew Cotham, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Alessandro Pl, Suite A40, Pasadena, CA 91105 Phone: 323-401-1935 | |
Ms. Salwa Seif El Deen Abdell Aal, RPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1650 E Walnut St, Suite A, Pasadena, CA 91106 Phone: 626-683-9959 Fax: 626-683-9969 |